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A B S T R A C T
Background
It has recently been argued that unsafe medical injections are a major transmission route of
HIV infection in the generalised epidemics of sub-Saharan Africa.
Methods and Findings
We have analysed the pattern of injections in relation to HIV incidence in a population cohort
in Manicaland in a rural area of Zimbabwe. In Poisson regression models, injections were not
found to be associated with HIV in males (rate ratio = 0.33; 95% confidence interval: 0.07 to
1.46) or females (rate ratio = 1.04; 95% confidence interval: 0.59 to 1.85).
Conclusion
It is important that unsafe medical injections can be confidently excluded as a major source
of HIV infection. In rural Zimbabwe the evidence is that they can.
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Introduction
The widely held belief that heterosexual transmission is the
driving force behind sub-Saharan Africa’s (SSA’s) HIV
epidemic [1] has recently been questioned [2]. According to
Gisselquist and colleagues, investigators have overlooked the
importance, and indeed suppressed analysis, of unsafe
medical injections as a route of transmission for HIV.
Hitherto, assessments of this hypothesis have largely relied
on ecological analyses—relating population-level data on
unsafe injections to the distribution of HIV prevalence [3,4].
The absence of investigation into the role of unsafe
injections, based on the assumed predominance of sexual
transmission, has rightly been criticised. However, this
criticism trivialises the difﬁculty of collecting and analysing
relevant ﬁeld data.
Presently, the only published data on the possible
contribution of injections to HIV transmission in SSA come
from rural Uganda, where Kiwanuka et al. demonstrated no
association of injections with HIV incidence [5]. Data from
other SSA countries with generalised epidemics where spread
has varied in scale and pattern are required to inform this
debate.
In this paper, we analyse data from a population cohort in
Manicaland in rural Zimbabwe. We describe the determinants
of injections in adults and then test the association between
injections and incidence of HIV infection.
Methods
Data were analysed from the baseline (1999/2000) and
follow-up (2002/2003) rounds of a cohort of adults in the
Manicaland HIV/STD Prevention Study. Eligible men and
women aged 15 to 54 were recruited based on an initial
household survey [6]. In response to the awakening con-
troversy, a question exploring exposure to injection was
added two-thirds of the way through follow-up. Thus, data
were available from individuals from four of the 12 study
sites. In these sites, 505 males and 1,342 females were
interviewed, representing a follow-up of 69.7% of individuals
interviewed at baseline. The subset of individuals who were
HIV-negative at baseline (n = 1,606; 83.6%) was used for all
analyses except for the examination of rates of injections
stratiﬁed by HIV status at baseline.
At follow-up, participants were asked whether they had
received an injection or had been pricked by a needle since
the baseline interview. A range of health and socio-
demographic data were also collected, including self-reported
history of sexually transmitted disease (STD) symptoms.
Reports on STD symptoms were from the 1-y period before
the follow-up interview, and thus did not correspond to the
entire 3-y follow-up period. HIV serological testing was
performed on dried blood spots using a highly sensitive and
speciﬁc antibody dipstick assay [7].
Ethical approval for this study was granted by the Medical
Research Council of Zimbabwe (MRCZ/A/681) and the
Applied and Qualitative Research Ethics Committee, Oxford
University, United Kingdom (N97.039). Written informed
consent was sought from study participants.
The objective of this analysis was to test the plausibility that
injections are an important risk factor for HIV incidence.
Having received an injection was modelled as a proximate
cause with demographic variables, sexual behaviour, and
STDs acting as potential confounders. Determinants of
injections were analysed with univariable and multivariable
Poisson regression models of incidence rate ratios (RRs).
Attributes were retained in age-adjusted multivariable
models if the stratum-speciﬁc RR differed from one and
had a Wald-test p-value  0.1. Using the same strategy,
models were then ﬁtted with HIV as the outcome variable.
Results
Overall, 744 out of 1,847 individuals (40.3%) reported
having received an injection or needle prick during the 3-y
follow-up period. Females reported more injections than
males (RR = 1.93). Rates were not signiﬁcantly higher for
individuals who were HIV positive at baseline (RR = 1.07,
p= 0.81 for males; RR = 1.13, p= 0.28 for females) (Table 1).
Being widowed, separated, or divorced was the only
attribute associated with increased rates of injections for
males (Table 1). For females, STD symptoms and childbearing/
pregnancy were signiﬁcant in adjusted models (Table 1).
There were 67 HIV seroconversions (48 females and 19
males); 13 (19%) of those seroconverting reported not having
had sex in the inter-survey period, and 40 (60%) reported not
having had an injection during the period (Table 2).
There was no signiﬁcant association between injections and
HIV incidence among either males or females—in either
unadjusted or adjusted models. For males, HIV seroconver-
sion rates were elevated amongst 25- to 44-y-olds, sexually
active individuals, and those who had suffered STD symp-
toms, though none of these attributes reached levels of
statistical signiﬁcance (Table 2). For females, having multiple
sexual partners, having STD symptoms, and being widowed/
separated/divorced were associated with increased HIV
incidence. Childbearing/pregnancy, which was strongly asso-
ciated with injections (see Table 1), had no association with
HIV incidence (Table 2).
Discussion
These data, from a population cohort in rural Zimbabwe,
suggest that—at the population level—injections are not a
major route of HIV transmission. There was a very slight,
non-signiﬁcant association between injections and HIV
amongst females. Could this association achieve signiﬁcance
with a greater sample size or more events? Given the strong
association between STD symptoms and both injections and
HIV incidence, this is possible, but would likely be a result of
residual confounding. In other words, both HIV and
injections have a common association with STDs. It has been
argued that the association between sexual activity and HIV is
confounding between STDs and pregnancy and injections
and that it is the injections that are causal. Our analysis does
indeed ﬁnd these associations—but ﬁnds STD symptoms the
strongest predictor of new HIV infections.
Our measure of injection risk is unambiguous but lacks
many dimensions relating to unsafe injections. Presently, we
have collected data about the receipt of injections and other
needle pricks. Thus, the exposures in these analyses are not
restricted to injections received from the health-care
sector—the source that Gisselquist et al. originally hypothe-
sized as a major route of transmission [2]. Also, these data
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reﬂect only whether an individual had an injection or not—
rather than the number of injections received. World Health
Organization estimates suggest that the number of injections
people receive is not evenly distributed in SSA populations
[8].
Thirteen of 67 individuals seroconverting in this study
reported no sexual partners in the inter-survey period. Only
four of these 13 reported never having had sex. This leads us
to suspect that incorrect categorisation of HIV status at
baseline in addition to misreporting of sexual behaviour may
explain some of these infections: it is possible that a
proportion of the nine individuals who reported having had
sex in their lifetime but not in the inter-survey period had
been recently infected but had not yet seroconverted at the
time of the baseline testing [9]. In this scenario, their
exposure would have occurred prior to baseline, rather than
in the follow-up period. Recall biases may also play a role,
given the relatively long follow-up of 3 y [10]. Non-regular
partners, especially those from the beginning of the recall
period, may have been under-reported. Eliciting accurate
reporting of sexual activity is notoriously difﬁcult in Africa
and elsewhere, though the use of informal conﬁdential voting
interviews has decreased social desirability biases in this
cohort [11]. Nonetheless, the cases (n = 4) where individuals
seroconverted who had reported never having had sex may
still be a product of social desirability reporting bias. Clearly,
incidence data offer the most explanatory power in elucidat-
ing the determinants of the HIV epidemic, but these
anomalous cases also highlight the difﬁculties of collecting
time-varying sexual behaviour and serostatus information.
Interestingly, in light of expected HIV-associated disease
and care, individuals who were HIV positive at baseline did
Table 1. Univariable and Multivariable Poisson Regression Models of Incidence of Injections and Needle Pricks—Presented Separately
for Males and Females
Attribute
Category
Attribute Number Who
Reported Injection(s)
PYAR Rate per
1,000 PYAR
Unadjusted Adjusteda
RR [95% CI] p RR [95% CI] p
Males
HIV status HIV negative at baseline 115 1,582 72.7 1
HIV positive at baseline 14 180 77.8 1.07 [0.61–1.86] 0.81
Age (in years) 17–19 3 34 86.7 0.93 [0.27–3.17] 0.90 0.69 [0.16–3] 0.78
20–24 37 623 59.4 0.64 [0.36–1.13] 0.12 0.68 [0.38–1.23] 0.30
25–34 40 565 70.7 0.76 [0.43–1.34] 0.34 0.84 [0.48–1.5] 0.65
35–44 18 177 101.6 1.09 [0.56–2.11] 0.80 1.14 [0.58–2.23] 0.72
45þ 17 182 93.4 1 1
Number of sexual
partners
0 partnersb 21 327 64.1 1
1 partnerb 37 514 71.9 1.12 [0.66–1.92] 0.68
.1 partnerb 57 740 77.0 1.20 [0.73–1.98] 0.47
STD symptoms No STD symptomsc 104 1,452 71.6 1
STD symptomsc 11 130 84.5 1.18 [0.63–2.2] 0.60
Marital status Never been married 47 809 58.1 1 1
Widowed/separated/divorced 9 61 146.7 2.53 [1.24–5.15] 0.011 2.31 [1.04–5.12] 0.047
Currently married 59 712 82.8 1.43 [0.97–2.09] 0.070 1.26d [0.77–2.08] 0.31
Females
HIV status HIV negative at baseline 525 3,739 140.4 1
HIV positive at baseline 95 600 158.3 1.13 [0.91–1.4] 0.28
Age (in years) 17–19 41 272 150.2 1.38 [0.95–1.99] 0.091 1.47 [0.99–2.7] 0.065
20–24 98 685 142.9 1.31 [0.98–1.74] 0.066 1.13 [0.83–1.56] 0.31
25–34 152 995 152.8 1.40 [1.08–1.82] 0.012 0.17 [0.88–1.56] 0.23
35–44 142 977 145.3 1.33 [1.02–1.73] 0.034 1.20 [0.91–1.58] 0.16
45þ 89 815 109.1 1 1
Number of sexual
partners
0 partnersb 80 770 103.9 1 1
1 partnerb 417 2,816 148.1 1.43 [1.12–1.81] 0.004 1.27 [1.00–1.62] 0.048
.1 partnerb 25 159 156.3 1.50 [0.96–2.36] 0.074 1.31d [0.82–2.11] 0.18
STD symptoms No STD symptomsc 420 3,191 131.6 1 1
STD symptomsc 102 555 183.8 1.40 [1.12–1.73] 0.002 1.39 [1.11–1.73] ,0.001
Marital status Never been married 63 523 120.4 1
Widowed/separated/divorced 70 561 124.6 1.03 [0.74–1.45] 0.84
Currently married 389 2,661 146.1 1.21 [0.93–1.58] 0.15
Childbearing/
pregnancy
Not had child/
not been pregnantb
297 2,463 120.6 1 1
Had child/been pregnantb 213 1,233 172.7 1.43 [1.22–1.71] ,0.001 1.30 [1.06–1.59] 0.034
Reported injections and person years may not add up across different attributes because of missing data.
a Adjusted for age and attributes significant at p  0.1 (Wald test).
b Exposure between baseline and follow-up (approximately 3 y).
c Exposure in the 1 y prior to follow-up.
d Not significant but shown to demonstrate the direction of effect.
CI, confidence interval; PYAR, person years at risk.
DOI: 10.1371/journal.pmed.0020037.t001
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not have higher rates of injections than individuals who were
HIV negative. Injections were found to be highly associated
with childbirth/pregnancy. HIV-positive women—and espe-
cially those at advanced stages of infection—are known to
experience reduced fertility [12]. Therefore, a reduction in
use of maternal health services may partially explain why
injections were not more common in the HIV-positive
population. A more discriminating measure of exposure,
including the reason for injection, could help to explain this
observation.
Had injections proven to be a risk factor for HIV
incidence, further investigations would have been needed to
determine the source and types of risky needle pricks.
However, no such association was found. Unsafe injections
are unacceptable, but this evidence suggests that they do not
play a major role in the transmission of HIV in rural
Zimbabwe.
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Patient Summary
Background There is a lot of controversy over whether the spread of HIV
in sub-Saharan Africa is predominantly caused by unsafe sexual
practices, or whether unsafe medical injections given by health
professionals might also have a prominent part to play. A recent paper
suggested that unsafe medical injections were important.
What Did the Authors Do? In an ongoing survey in rural Zimbabwe
between 1999/2000 and 2002/3 that was trying to assess why some
individuals get infected with HIV, the authors asked 505 men and 1,342
women a number of questions. They asked them about their sexual
history, whether they had children, and whether they received injections.
They tested the adults for HIV at the beginning and end of the study
period.
What Did They Find? 744 people had had a medical injection and 67
people acquired HIV. There was no evidence overall that injections were
linked with an increase in HIV infection. The strongest link with HIV
infection was with symptoms of sexually transmitted diseases (in other
words, people with these symptoms were more likely to acquire HIV
infection).
What Do These Findings Mean? These findings suggest that although
it is still possible for an individual to get HIV through unsafe medical
injections, overall in this population in Zimbabwe, unsafe injections are
not an important cause of HIV infection. Hence policymakers should
concentrate more on trying to prevent infection from unsafe sex.
Where Can I Get More Information?
Information on safe sex: http://www.thebody.com/safesex.html
World Health Organization Web page on reducing the risk of HIV infec-
tion in drug users who inject drugs intravenously: http://www.who.int/
hiv/topics/harm/reduction/en/
Fact sheet from the Joint United Nations Programme on HIV/AIDS on
HIV/AIDS in Zimbabwe: http://www.unaids.org/html/pub/publications/
fact-sheets01/Zimbabwe_en_pdf.htm
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